Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of lisdexamfetamine in adults with moderate to severe binge eating disorder
2012-003310-14Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing Lisdexamfetamine dimesylate with Placebo (2 arms). Primary endpoint: Change from baseline in number of binge days per week. Started Jan 2013; status: terminated.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on 2012-003310-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003310-14.